| HOME >> MEDICINE >> TECHNOLOGY |
EMEA Issues Positive Opinion for Thalidomide Use in Multiple
Myeloma 38
Global Regulatory Developments for the Use of Revlimid® in
Multiple Myeloma 39
Takeda Gains FDA Approval to Promote Velcade 39
Health Canada Approves VELCADE 40
Genzyme Receives FDA Certification for Mozobil 40
Celgene's Thalidomide Pharmion Receives Marketing Authorization 41
GlaxoSmithKline Forms Alliance with OncoMed for Developing
Cancer Therapeutics 41
Cyclacel Signs Agreement to Acquire ALIGN Pharmaceuticals 41
Biogen and Genentech to Jointly Develop and Commercialize New
Blood Cancer Drug 42
Aegera Therapeutics Acquires LymphoSign Inc 42
Velcade Gains Subsidy 43
Inex Pharmaceuticals Spins Off Biotechnology Business into
Tekmira Pharmaceuticals 43
MilleGen Enters into Collaboration with LFB 43
Access Pharmaceuticals to Acquire Somanta 43
TopoTarget to Acquire Apoxis SA 43
Genentech Inks Exclusive Global Licensing Agreement with
Seattle Genetics 44
Celgene Agrees to Acquisition of Pharmion 44
PerkinElmer Plans Acquisition of ViaCell 44
Favrille Announces Acquisition of Monoclonal Antibody Range
from Diversa 45
Johnson & Johnson Secures Contract worth US$112 Million 45
Bioniche Pharma to Acquire Branded Pharmaceutical from Nabi
Biopharmaceuticals 45
Ziopharm Commences Phase II Clinical Trial of ZIO-101 46
FDA Approves Pluristem's Pre-IND Application of PLX-I 46
Merck Pharmaceuticals Commences Phase I Study for R763 Kinase
Inhibitor 46
Swissmedic Approves Celgene's REVLIMID Oral Cancer Drug 46
Celgene's REVLIMID Receives EU's Marketing Authorization 47
FDA Approves Applicatio
'/>"/>
| SOURCE Reportlinker Copyright©2009 PR Newswire. All rights reserved |